$34.25
0.75[2.24%]
At close: Apr 26
$34.25
0[0.00%]
After Hours: 4:16PM EDT
Corbus Pharmaceuticals
(NASDAQ:CRBP)Corbus Pharmaceuticals Stock (NASDAQ:CRBP), Analyst Ratings, Price Targets, Predictions
Corbus Pharmaceuticals Holdings Inc has a consensus price target of $35.67, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Jefferies, and Oppenheimer on March 13, 2024, March 6, 2024, and January 29, 2024. With an average price target of $51.67 between Oppenheimer, Jefferies, and Oppenheimer, there's an implied 50.85% upside for Corbus Pharmaceuticals Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Jefferies
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Corbus Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/13/2024 | CRBP | Buy Now | Corbus Pharmaceuticals | $34.25 | 69.34% | Oppenheimer | Jeff Jones | $51 → $58 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | CRBP | Buy Now | Corbus Pharmaceuticals | $34.25 | 34.31% | Jefferies | Maury Raycroft | $4 → $46 | Upgrade | Hold → Buy | Get Alert |
| 01/29/2024 | CRBP | Buy Now | Corbus Pharmaceuticals | $34.25 | 48.91% | Oppenheimer | Jeff Jones | $20 → $51 | Maintains | Outperform | Get Alert |
| 08/09/2023 | CRBP | Buy Now | Corbus Pharmaceuticals | $34.25 | -35.77% | Oppenheimer | Jeff Jones | → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2023 | CRBP | Buy Now | Corbus Pharmaceuticals | $34.25 | -35.77% | Oppenheimer | Jeff Jones | → $22 | Upgrade | Perform → Outperform | Get Alert |
| 03/08/2023 | CRBP | Buy Now | Corbus Pharmaceuticals | $34.25 | -91.24% | HC Wainwright & Co. | Andrew Fein | → $3 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | CRBP | Buy Now | Corbus Pharmaceuticals | $34.25 | -91.24% | HC Wainwright & Co. | Andrew Fein | → $3 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Corbus Pharmaceuticals (CRBP)?
The latest price target for Corbus Pharmaceuticals (NASDAQ: CRBP) was reported by Oppenheimer on March 13, 2024. The analyst firm set a price target for $58.00 expecting CRBP to rise to within 12 months (a possible 69.34% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corbus Pharmaceuticals (CRBP)?
The latest analyst rating for Corbus Pharmaceuticals (NASDAQ: CRBP) was provided by Oppenheimer, and Corbus Pharmaceuticals reiterated their outperform rating.
When was the last upgrade for Corbus Pharmaceuticals (CRBP)?
The last upgrade for Corbus Pharmaceuticals Holdings Inc happened on March 6, 2024 when Jefferies raised their price target to $46. Jefferies previously had a hold for Corbus Pharmaceuticals Holdings Inc.
When was the last downgrade for Corbus Pharmaceuticals (CRBP)?
There is no last downgrade for Corbus Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Corbus Pharmaceuticals (CRBP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corbus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corbus Pharmaceuticals was filed on March 13, 2024 so you should expect the next rating to be made available sometime around March 13, 2025.
Is the Analyst Rating Corbus Pharmaceuticals (CRBP) correct?
While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a reiterated with a price target of $51.00 to $58.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $34.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.